Eli Lilly and Company
Combination Therapy
Last updated:
Abstract:
The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.
Status:
Application
Type:
Utility
Filling date:
5 Jan 2021
Issue date:
29 Apr 2021